Affinage

KDM6B

Lysine-specific demethylase 6B · UniProt O15054

Length
1643 aa
Mass
176.6 kDa
Annotated
2026-04-28
100 papers in source corpus 50 papers cited in narrative 50 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

KDM6B (JMJD3) is a Jumonji C domain-containing histone demethylase that removes repressive H3K27me2/me3 marks from gene promoters and gene bodies, functioning as a master epigenetic switch for lineage commitment, immune cell polarization, metabolic gene regulation, and neuronal differentiation. KDM6B is recruited to specific genomic loci by diverse transcription factors—including p53, ISL1, HOXC9, KLF2, Hes1, Rreb1, NF-κB, and Tau—where it erases H3K27me3 to permit transcriptional activation and facilitate RNA polymerase II elongation through Polycomb-repressed chromatin (PMID:22770241, PMID:23243002, PMID:24797517, PMID:27105846, PMID:36028572). Beyond its catalytic activity, KDM6B operates through demethylase-independent mechanisms: it recruits the E3 ubiquitin ligase TRIM26 to target PHF20 for degradation during somatic cell reprogramming, forms a complex with the RNA helicase DDX21 to resolve R-loops at inflammatory gene loci, and regulates AP-1 target gene expression in hematopoietic stem cells independently of H3K27me3 changes (PMID:23452852, PMID:31251802, PMID:30936419). KDM6B activity is itself regulated at transcriptional (by STAT3, VDR, ERα, AR, CSL, HIF-2α) and metabolic (α-ketoglutarate/succinate ratio) levels, and at the protein stability level through USP7-mediated deubiquitination, integrating diverse signaling inputs into chromatin state decisions across development, immunity, and disease (PMID:32299951, PMID:35443173, PMID:33434305).

Mechanistic history

Synthesis pass · year-by-year structured walk · 17 steps
  1. 2010 High

    Establishing that KDM6B is recruited to specific promoters by transcription factors (Hes1) to demethylate H3K27me3 and activate lineage-specific gene expression resolved how a broadly expressed demethylase achieves target specificity during neuronal differentiation.

    Evidence Co-IP of Jmjd3-Hes1, ChIP at Mash1 promoter, catalytic mutant controls in P19 cells

    PMID:20506217

    Open questions at the time
    • Whether Hes1-mediated recruitment operates in primary neurons in vivo
    • Structural basis of the Jmjd3-Hes1 interaction
  2. 2011 High

    Demonstrating that KDM6B is itself a transcriptional target of VDR signaling and then co-mediates vitamin D-induced gene activation established a feed-forward regulatory logic in which signaling pathways first induce KDM6B expression and then exploit its demethylase activity.

    Evidence shRNA, catalytically inactive mutant, ChIP, cycloheximide sensitivity in SW480-ADH colon cancer cells

    PMID:21890490

    Open questions at the time
    • Whether other nuclear hormone receptors use the same feed-forward circuit
    • Genome-wide target repertoire of VDR-KDM6B cooperation
  3. 2012 High

    Showing that KDM6B removes H3K27me3 at HOX loci to drive osteogenic over adipogenic MSC fate, and at SNAI1 to drive EMT, established KDM6B as a binary lineage switch operating through locus-specific H3K27me3 erasure at master regulator genes.

    Evidence shRNA/OE in human MSCs with osteogenic/adipogenic readouts; ChIP at SNAI1 promoter during TGF-β-induced EMT in mammary epithelial cells

    PMID:22770241 PMID:23152497

    Open questions at the time
    • What determines KDM6B target selectivity among different HOX clusters
    • Whether KDM6B acts alone or requires cofactors at these loci
  4. 2012 High

    Genome-wide ChIP-seq revealed that JMJD3 co-localizes with RNAPII along gene bodies of TGF-β-responsive genes, establishing that KDM6B facilitates transcriptional elongation by clearing intragenic H3K27me3 barriers—not just promoter derepression.

    Evidence ChIP-seq for JMJD3 and RNAPII upon TGF-β treatment

    PMID:23243002

    Open questions at the time
    • Whether elongation facilitation is a general KDM6B function or context-specific
    • The mechanism by which KDM6B is loaded onto elongating RNAPII
  5. 2013 High

    Discovery that JMJD3 inhibits iPSC reprogramming through both a catalytic pathway (INK4a/Arf derepression) and a demethylase-independent pathway (TRIM26-mediated PHF20 ubiquitination) fundamentally expanded the functional repertoire of KDM6B beyond H3K27me3 erasure.

    Evidence Active-site mutant analysis, Co-IP of JMJD3-TRIM26, reconstituted ubiquitination assays, genetic epistasis in MEF reprogramming

    PMID:23452852

    Open questions at the time
    • Whether the TRIM26-PHF20 axis operates in contexts other than reprogramming
    • Structural determinants of the demethylase-independent scaffold function
  6. 2013 High

    Demonstrating that KDM6B/EED balance regulates trophectoderm vs. ICM specification via H3K27me3 at CDX2/GATA3 placed KDM6B at the first mammalian cell fate decision, showing it counteracts PRC2 at lineage master regulators in preimplantation embryos.

    Evidence Gain/loss-of-function in preimplantation mouse embryos, ChIP, implantation phenotype

    PMID:23671187

    Open questions at the time
    • How relative KDM6B/EED levels are set asymmetrically in outer vs. inner blastomeres
    • Whether UTX contributes at this stage
  7. 2014 High

    Finding that p53 physically recruits JMJD3 to p53 target promoters and enhancers genome-wide after DNA damage, enabling H3K27me3-to-H3K27ac switching, established KDM6B as a chromatin effector of the DNA damage response.

    Evidence Co-IP of JMJD3-p53 via tetramerization domain, genome-wide ChIP-seq after DNA damage

    PMID:24797517

    Open questions at the time
    • Whether JMJD3 recruitment selects which p53 targets are activated vs. repressed
    • Role at p53-dependent enhancers vs. promoters
  8. 2015 High

    Conditional double KO of Jmjd3/Utx in thymocytes showed redundant demethylase-dependent control of S1pr1 and T cell egress, while Jmjd3-specific recruitment by Rreb1 at BAT-selective genes demonstrated tissue-specific transcription factor partnerships that specify KDM6B target choice.

    Evidence Conditional KO in thymocytes with catalytically inactive Uty rescue; transgenic Jmjd3 gain/loss-of-function in brown adipocytes with ChIP-seq and Rreb1 recruitment assays

    PMID:26328764 PMID:26625958

    Open questions at the time
    • How many transcription factors recruit KDM6B vs. UTX specifically
    • Whether Rreb1 interaction is direct or bridged
  9. 2016 High

    Identification of ISL1 as a cardiac progenitor-specific recruiter of JMJD3 to Myocd/Mef2c enhancers, and NF-κB as a wound-healing recruiter to inflammatory gene promoters, generalized the model that diverse transcription factors confer locus specificity on KDM6B.

    Evidence Co-IP of ISL1-JMJD3 with conditional KO in cardiac progenitors; Co-IP of JMJD3-NF-κB with ChIP in keratinocyte wound models

    PMID:26802933 PMID:27105846

    Open questions at the time
    • Whether ISL1 modulates KDM6B catalytic rate directly or just provides targeting
    • How JMJD3-NF-κB interaction is regulated temporally in wound healing
  10. 2017 High

    Catalytically inactive Jmjd3 knock-in mice phenocopied the Jmjd3 KO for axial skeletal patterning with elevated H3K27me3 at Hox loci, confirming that demethylase activity is the essential function for Hox gene regulation and body axis specification in vivo.

    Evidence Jmjd3 KO and catalytic-dead knock-in mice, ChIP at Hox loci in embryonic tailbuds

    PMID:28188179

    Open questions at the time
    • Whether the demethylase-independent functions are dispensable for development at specific stages
    • Redundancy with UTX at Hox loci
  11. 2018 High

    Discovery that fasting-activated PKA signaling induces a JMJD3-SIRT1-PPARα complex that epigenetically activates hepatic β-oxidation genes (but not gluconeogenic genes) revealed KDM6B as a metabolic sensor linking nutritional state to chromatin remodeling, with liver-specific KDM6B loss causing hepatosteatosis.

    Evidence Co-IP of JMJD3-SIRT1-PPARα, ChIP at β-oxidation gene promoters, liver-specific KD with metabolic phenotyping in diet-induced obese mice

    PMID:29911994

    Open questions at the time
    • Whether KDM6B enzymatic activity or scaffold function mediates β-oxidation gene activation
    • How gene selectivity (β-oxidation vs. gluconeogenesis) is achieved
  12. 2019 High

    Identification of the JMJD3-DDX21 complex that resolves R-loops at the ENPP2 locus in a demethylase-independent manner uncovered a novel non-catalytic chromatin function for KDM6B, linking it to co-transcriptional RNA processing and genome stability.

    Evidence Mass spectrometry identification, Co-IP of JMJD3-DDX21, CRISPR enhancer deletion, R-loop detection assays

    PMID:31251802

    Open questions at the time
    • How widespread R-loop resolution by JMJD3-DDX21 is genome-wide
    • Whether R-loop resolution contributes to inflammatory gene regulation beyond ENPP2
  13. 2019 High

    Showing that KDM6B-deficient HSCs upregulate AP-1/Fos/Jun target genes without H3K27me3 changes, and that AP-1 targeting rescues HSC function, established a third demethylase-independent mechanism and placed KDM6B in hematopoietic stem cell maintenance under stress.

    Evidence Conditional Kdm6b KO mice, HSC repopulation assays, RNA-seq, AP-1 genetic rescue

    PMID:30936419

    Open questions at the time
    • Biochemical mechanism by which KDM6B restrains AP-1 activity
    • Whether this function involves the TRIM26 or DDX21 pathways
  14. 2020 High

    Demonstration that temperature-dependent STAT3 phosphorylation represses Kdm6b transcription in turtle embryos, gating male sex determination, revealed KDM6B as a sensor node integrating environmental signals into developmental epigenetic programs.

    Evidence pSTAT3 ChIP at Kdm6b locus, Ca2+ influx manipulation, temperature shift experiments in turtle embryos

    PMID:32299951

    Open questions at the time
    • Whether this STAT3-KDM6B axis is conserved in other reptiles with temperature-dependent sex determination
    • Downstream KDM6B targets that specify male fate in this system
  15. 2021 High

    Metabolic regulation of KDM6B was established by showing that IFN-β alters the α-ketoglutarate/succinate ratio to inhibit JMJD3 catalytic activity, blocking JMJD3-IRF4-dependent M2 macrophage polarization—directly connecting cellular metabolism to KDM6B enzymatic function.

    Evidence Glutamine carbon tracing, metabolic flux analysis, α-ketoglutarate rescue of IFN-β-suppressed JMJD3-IRF4 pathway in macrophages

    PMID:35443173

    Open questions at the time
    • Whether succinate accumulation inhibits KDM6B by direct product inhibition or indirectly
    • Applicability to non-macrophage cell types
  16. 2021 High

    Myeloid-specific Kdm6b deletion enhanced antigen presentation and anti-tumor immunity in glioblastoma models, synergizing with anti-PD1, identifying KDM6B as a myeloid immune checkpoint operating through transcriptional maintenance of immunosuppressive mediators (Mafb, Socs3, Sirpa).

    Evidence Myeloid-specific KO mice, scRNA-seq and spatial transcriptomics in GBM models, anti-PD1 combination therapy

    PMID:37653141

    Open questions at the time
    • Whether therapeutic KDM6B inhibition broadly enhances anti-tumor immunity beyond GBM
    • Mechanism by which KDM6B maintains Mafb/Socs3 expression—direct H3K27me3 removal or indirect
  17. 2022 High

    Tau-dependent recruitment of KDM6B to VGLUT1/2 promoters in excitatory neurons, with conditional KO causing reduced spine density and learning/memory deficits, placed KDM6B in synaptic gene regulation and cognitive function.

    Evidence Conditional KDM6B KO in excitatory neurons, Co-IP of KDM6B-Tau, ChIP at VGLUT1/2 promoters, electrophysiology, behavioral testing

    PMID:36028572

    Open questions at the time
    • Whether KDM6B-Tau interaction is disrupted in tauopathies
    • Full repertoire of KDM6B-Tau co-regulated genes beyond VGLUTs

Open questions

Synthesis pass · forward-looking unresolved questions
  • The structural basis by which KDM6B is recruited by its diverse transcription factor partners, how its catalytic and non-catalytic functions are partitioned at individual loci, and whether therapeutic KDM6B modulation can be made cell-type-selective remain unresolved.
  • No crystal structure of KDM6B in complex with any recruiting transcription factor
  • No systematic comparison of catalytic vs. scaffold functions at the same locus
  • No clinical data on KDM6B-targeted therapies

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 17 GO:0042393 histone binding 9 GO:0140110 transcription regulator activity 3
Localization
GO:0005634 nucleus 9 GO:0005694 chromosome 4
Pathway
R-HSA-4839726 Chromatin organization 18 R-HSA-162582 Signal Transduction 8 R-HSA-168256 Immune System 8 R-HSA-1266738 Developmental Biology 7 R-HSA-74160 Gene expression (Transcription) 5
Partners
DDX21ISL1KLF2MAPTRREB1SIRT1TP53TRIM26
Complex memberships
JMJD3-DDX21JMJD3-SIRT1-PPARαJMJD3-TRIM26

Evidence

Reading pass · 50 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2012 KDM6B (JMJD3) promotes osteogenic differentiation of human MSCs by removing repressive H3K27me3 marks at HOX gene loci, thereby activating HOX expression and driving osteogenic commitment at the expense of adipogenic differentiation. shRNA knockdown, ChIP assays, overexpression in human MSCs with osteogenic/adipogenic differentiation readouts Cell Stem Cell High 22770241
2012 KDM6B promotes TGF-β-induced epithelial-mesenchymal transition (EMT) in mammary epithelial cells by removing H3K27me3 marks at the SNAI1 promoter, thereby stimulating SNAI1 expression and downstream mesenchymal gene induction. shRNA knockdown, overexpression, ChIP assays, TGF-β-induced EMT assays in mammary epithelial cells The Journal of Biological Chemistry High 23152497
2013 JMJD3 (KDM6B) inhibits somatic cell reprogramming to iPSCs through two pathways: (1) H3K27me3 demethylase-dependent upregulation of INK4a/Arf, and (2) a demethylase-independent pathway in which JMJD3 recruits the E3 ubiquitin ligase TRIM26 to target PHF20 for ubiquitination and degradation. Genetic KO/OE in MEFs, iPSC colony assays, Co-IP for JMJD3-TRIM26 interaction, ubiquitination assays, active-site mutant analysis Cell High 23452852
2011 KDM6B expression is induced by vitamin D receptor (VDR) signaling in a VDR-dependent, cycloheximide-sensitive manner; KDM6B then co-mediates 1,25(OH)2D3-induced target gene expression and an epithelial adhesive phenotype in colon cancer cells by modulating H3K27me3 at target gene promoters. shRNA knockdown, inactive mutant expression, promoter activation assays, ChIP, cycloheximide treatment in SW480-ADH colon cancer cells Human Molecular Genetics High 21890490
2012 JMJD3 facilitates RNA polymerase II progression through H3K27me3-enriched gene bodies of TGF-β-responsive genes by demethylating H3K27me3 along intragenic regions, enabling transcriptional elongation. ChIP-seq, ChIP-qPCR, genome-wide analysis of RNAPII and JMJD3 co-localization upon TGF-β treatment Molecular Biology of the Cell High 23243002
2013 Jmjd3 reduces H3K27me3 marks at the Brachyury promoter and facilitates recruitment of β-catenin, enabling Wnt-signal-induced mesoderm differentiation; Jmjd3 ablation in mouse ESCs compromises mesoderm and subsequent endothelial and cardiac differentiation without affecting pluripotency. Jmjd3 ablation in mouse ESCs, ChIP assays at Brachyury promoter, differentiation assays Circulation Research High 23856522
2013 KDM6B and EED (PRC2 component) combinatorially regulate the first mammalian cell lineage commitment: relative KDM6B/EED levels determine H3K27me3 deposition at CDX2 and GATA3 chromatin domains, activating these TE-specific master regulators in trophectoderm and repressing them in ICM; KDM6B depletion combined with EED gain-of-function abrogates CDX2/GATA3 expression and prevents embryo implantation. Gain- and loss-of-function in preimplantation mouse embryos, ChIP, PRC2 recruitment assays Molecular and Cellular Biology High 23671187
2014 JMJD3 interacts with tumor suppressor p53 via the p53 tetramerization domain; following DNA damage, JMJD3 is transcriptionally upregulated and is recruited in a p53-dependent manner to p53 target promoters and enhancers genome-wide, where it removes H3K27me3/me2 to permit H3K27 acetylation. Co-IP, genome-wide ChIP-seq of JMJD3, DNA damage assays, p53-dependent recruitment experiments PLoS One High 24797517
2014 Histone demethylase Jmjd3 is required for differentiation of PKC-positive rod-ON bipolar cells in the retina by enabling lineage-specific H3K27me3 demethylation at the Bhlhb4 locus; overexpression of Bhlhb4 rescues the loss of these cells in Jmjd3-knockdown retina. Jmjd3 loss-of-function in developing retina, ChIP at Bhlhb4 locus, Bhlhb4 rescue overexpression PNAS High 24572572
2015 Jmjd3 and Utx redundantly promote H3K27me3 removal at a subset of genes required for terminal thymocyte differentiation, most critically at the S1pr1 locus (encoding a sphingosine-1-phosphate receptor for thymocyte egress); the catalytic demethylase activity is required, as the catalytically inactive Uty homolog cannot rescue S1pr1 expression. Conditional inactivation of Jmjd3 and Utx in intrathymic CD4+ T-cell precursors in mice, ChIP for H3K27me3, RNA analysis, rescue experiments with catalytically inactive Uty Nature Communications High 26328764
2015 Jmjd3-catalyzed removal of H3K27me3, in part through recruitment by the transcription factor Rreb1, is required for expression of BAT-selective genes and development of brown adipocytes; a significant subset of BAT-selective (but not common fat or WAT-selective) genes are demarcated by H3K27me3 in preadipocytes. Jmjd3 gain- and loss-of-function transgenic mice, ChIP-seq for H3K27me3, adipocyte differentiation assays in vitro and in vivo, Rreb1-mediated recruitment assays Developmental Cell High 26625958
2016 JMJD3 interacts with NF-κB in keratinocytes and cooperates to demethylate H3K27me3 at promoters of inflammatory, matrix metalloproteinase, and growth factor genes, driving keratinocyte wound healing; inactivation of either JMJD3 or NF-κB impairs wound healing. Co-IP for JMJD3-NF-κB interaction, ChIP at gene promoters, JMJD3/NF-κB knockdown in vitro and in vivo wound healing models Journal of Investigative Dermatology High 26802933
2016 JMJD3 and NF-κB cooperate to activate Notch1 expression by demethylating H3K27me3 at the Notch1 promoter in wounded keratinocytes; Notch1 then activates RhoU and PLAU to promote filopodia formation and cell migration during wound healing. ChIP assays at Notch1 promoter, knockdown/inactivation of JMJD3, NF-κB, and Notch1 in vitro and in vivo wound models Scientific Reports High 28747631
2016 JMJD3 physically interacts with ISL1 in cardiac progenitor cells; ISL1 recruits JMJD3 to enhancers of cardiac transcription factor genes (Myocd, Mef2c) and modulates its H3K27me3 demethylase activity; conditional depletion of JMJD3 impairs cardiac progenitor differentiation, phenocopying ISL1 depletion. Co-IP of ISL1-JMJD3, ChIP at Myocd and Mef2c enhancers, conditional JMJD3 deletion in cardiac progenitors, ESC differentiation assays Nucleic Acids Research High 27105846
2016 Neuronal stimulation (NMDA) induces CREB-p/CBP-dependent and JMJD3-dependent H3K27me3 demethylation at Bdnf promoters II and VI in mature hippocampal neurons, displacing EZH2 and enabling fast Bdnf transcription; JMJD3-mediated demethylation facilitates RNAPII progression through Polycomb-repressed Bdnf loci. ChIP in hippocampal neurons, NMDA stimulation, EZH2 displacement assays, histone mark analysis Nature Communications Medium 27010597
2017 DHEA activates TrkA phosphorylation, which triggers an Akt1/2-CREB signaling cascade that induces Jmjd3 expression in microglia; Jmjd3 then controls inflammatory gene expression and microglial polarization, mediating DHEA's anti-inflammatory effects. In vivo LPS-induced neuroinflammation mouse model, in vitro microglia culture, pathway inhibitor studies, Jmjd3 KD Molecular Psychiatry Medium 28894299
2017 STAT3 binds the Jmjd3 promoter and represses its transcription in glioblastoma stem cells; STAT3 inhibition leads to Jmjd3 upregulation and H3K27 demethylation of neural differentiation genes; Jmjd3 overexpression slows glioblastoma stem cell growth and neurosphere formation. ChIP of STAT3 at Jmjd3 promoter, STAT3 inhibitor treatment, Jmjd3 KD and OE, neurosphere formation assays PLoS One Medium 28384648
2017 KDM6B is required for activity-regulated neuronal survival preconditioning; Kdm6b knockdown abolishes bicuculline/4-AP-induced preconditioning of neuronal survival and impairs inducibility of a discrete set of inflammation-related genes without broadly disrupting activity-regulated transcription. Kdm6b KD in cultured hippocampal neurons, bicuculline/4-AP stimulation, RNA-seq, cell survival assays, pilocarpine-induced seizure in vivo Molecular and Cellular Neurosciences Medium 24983519
2018 JMJD3, together with SIRT1 and PPARα, forms a positive autoregulatory loop activated by fasting-induced PKA signaling; JMJD3 acts as a gene-specific transcriptional partner of SIRT1 and epigenetically activates mitochondrial β-oxidation genes (Fgf21, Cpt1a, Mcad) by removing H3K27me3, without affecting gluconeogenic genes; liver-specific Jmjd3 knockdown causes intrinsic β-oxidation defects, hepatosteatosis, and glucose/insulin intolerance. Liver-specific KD, Co-IP of JMJD3-SIRT1-PPARα complex, ChIP at β-oxidation gene promoters, in vivo metabolic phenotyping in diet-induced obese mice Journal of Clinical Investigation High 29911994
2018 JMJD3 is recruited to the β-MHC promoter in cardiomyocytes where it demethylates H3K27me3, promoting β-MHC expression and cardiac hypertrophy; overexpression of wild-type but not demethylase-defective JMJD3 induces hypertrophy, and JMJD3 silencing or GSK-J4 suppresses ISO-induced hypertrophy. ChIP at β-MHC promoter, WT vs. catalytic mutant JMJD3 overexpression, JMJD3 siRNA, GSK-J4 inhibitor treatment, in vivo isoproterenol model Molecular and Cellular Endocrinology High 29753027
2019 JMJD3 forms a novel complex with the RNA helicase DDX21; this JMJD3-DDX21 complex is recruited to the ENPP2 locus (via a distant enhancer) in a JMJD3-dependent and NF-κB-dependent manner upon LPS stimulation, where DDX21 resolves R-loops formed by nascent transcripts to promote ENPP2 transcription; JMJD3's role at ENPP2 is non-enzymatic (demethylase-independent). Mass spectrometry identification of JMJD3 interactors, Co-IP of JMJD3-DDX21, ChIP at ENPP2 locus, CRISPR-Cas9 enhancer deletion, R-loop detection assays Nucleic Acids Research High 31251802
2019 JMJD3 binds the promoter and gene body of the Pdlim4 gene by interacting with the zinc-finger transcription factor KLF2; JMJD3 deficiency in CD4+ T cells reduces PDLIM4 expression, impairing PDLIM4-mediated interaction between S1P1 and F-actin and thereby disrupting T cell trafficking from thymus to secondary lymphoid organs. Gene profiling and ChIP-seq in JMJD3-KO CD4+ T cells, Co-IP for JMJD3-KLF2, PDLIM4-S1P1-F-actin interaction assays, T cell trafficking experiments Journal of Clinical Investigation High 31393857
2019 Kdm6b is required for hematopoietic stem cell (HSC) self-renewal under inflammatory/proliferative stress; loss of Kdm6b leads to increased AP-1 transcription factor complex (Fos/Jun) and IER gene expression independently of H3K27me3 chromatin changes; targeting AP-1 restores function of Kdm6b-deficient HSCs, demonstrating a demethylase-independent mechanism. Conditional Kdm6b KO mice, HSC functional assays (repopulation), RNA-seq, AP-1 genetic targeting as epistasis rescue Leukemia High 30936419
2020 Temperature-dependent sex determination in turtle embryos is mediated by STAT3 phosphorylation at the female-producing (warmer) temperature; pSTAT3 binds the Kdm6b locus and represses Kdm6b transcription; Ca2+ influx (elevated at female temperature) mediates STAT3 phosphorylation, creating a temperature-sensitive regulatory cascade that blocks the male developmental pathway. STAT3 phosphorylation assays at different temperatures, ChIP of pSTAT3 at Kdm6b locus, Ca2+ influx measurements, Kdm6b transcription assays Science High 32299951
2020 JMJD3 in macrophages is regulated by KDM6B expression downstream of JAK/STAT and NF-κB pathways; palmitate (via TLR4/MyD88 signaling) induces Jmjd3 expression, causing removal of H3K27me3 from NF-κB-mediated inflammatory gene promoters and driving macrophage inflammatory activation in diabetic peripheral tissue. Tlr4-/- and MyD88-/- mice, palmitate treatment, ChIP at inflammatory gene promoters, GSK-J4 inhibitor in diabetic wound healing model European Journal of Immunology High 32662520
2021 Interferon-β controls the cellular α-ketoglutarate/succinate ratio (by increasing itaconate and succinate while restricting α-ketoglutarate); this metabolic shift potently blocks the JMJD3-IRF4-dependent pathway in macrophages, suppressing M2 polarization; supplementing α-ketoglutarate reverses IFNβ-mediated suppression of JMJD3-IRF4 responses. Metabolic flux analysis (glutamine carbon tracing), JMJD3-IRF4 pathway assays in GM-CSF/IL-4-activated macrophages, α-ketoglutarate supplementation rescue Cell Reports High 35443173
2021 JMJD3 in macrophages drives NF-κB-mediated inflammatory gene transcription via H3K27me3 removal; interferon-β regulates Jmjd3 expression via JAK/STAT; myeloid-specific JMJD3 genetic depletion (Jmjd3f/f Lyz2Cre+) preserves repressive H3K27me3 on inflammatory gene promoters and reduces AAA expansion in vivo. Single-cell RNA-seq of human AAA tissue, myeloid-specific KO mice, elastase/angiotensin II AAA models, ChIP for H3K27me3 at inflammatory gene promoters, pharmacological inhibition Journal of Experimental Medicine High 33779682
2021 JMJD3 promotes muscle stem cell (MuSC) adaptation to inflammation by removing H3K27me3 marks at the Has2 locus, initiating hyaluronic acid production via HAS2; this extracellular hyaluronic acid establishes a matrix that integrates signals directing MuSCs to exit quiescence; UTX does not substitute for JMJD3 in this process. Conditional KO of Jmjd3 vs. Utx in MuSCs, ChIP at Has2 locus, hyaluronic acid quantification, MuSC cell cycle re-entry assays Science High 35926054
2021 KDM6B promotes CDK4/6-pRB-E2F oncogenic pathway activity in MYCN-amplified neuroblastoma by maintaining H3K4me1 enhancer marks and chromatin accessibility at CTCF/BORIS binding sites; KDM6B inhibition increases H3K27me3 but decreases H3K4me1 at these sites, disrupting long-range chromatin interactions of MYCN and E2F target genes. KDM6B inhibition (GSK-J4), ChIP for H3K27me3 and H3K4me1, ATAC-seq for chromatin accessibility, CDK4/6 overexpression and Rb1 KO as resistance experiments Nature Communications High 34893606
2021 KDM6B promotes lung metastasis of osteosarcoma by directly mediating H3K27me3 demethylation at the LDHA gene locus, increasing LDHA expression and aerobic glycolysis; LDHA overexpression rescues the anti-metastatic phenotype of KDM6B knockdown. ChIP-seq and RNA-seq combined, ChIP-qPCR at LDHA locus, glycolysis assays, in vivo orthotopic lung metastasis model, LDHA rescue overexpression Theranostics High 33664867
2021 KDM6B is an androgen receptor (AR)-regulated gene; AR decreases KDM6B transcription; KDM6B demethylates H3K27me3 at the cyclin D1 promoter and cooperates with Smad2/3 to promote cyclin D1 expression and prostate cancer cell proliferation. ChIP at cyclin D1 promoter, AR regulation of KDM6B promoter, Co-immunoprecipitation of KDM6B-Smad2/3, in vitro and in vivo PCa models Cell Death & Disease Medium 33414463
2021 miR-15b targets and inhibits USP7; USP7 deubiquitinates and stabilizes KDM6B protein (MG132 increases KDM6B expression); reduced KDM6B (via miR-15b/USP7 axis) impairs osteoblast autophagy and differentiation in osteoporosis. miR-15b/USP7 binding validation, MG132 proteasome inhibitor experiments, USP7 OE restoring KDM6B, KDM6B KD in osteoblasts, in vivo OVX model Journal of Cellular and Molecular Medicine Medium 33434305
2021 KDM6B is required for virus-specific CD8+ T cell differentiation; rapid KDM6B upregulation prior to the first cell division initiates H3K27me3 removal at genes essential for T cell proliferation and differentiation; KDM6B inhibition limits the magnitude of primary CD8+ T cell responses and memory formation. Genome-wide ChIP-seq for H3K27me3, ATAC-seq, RNA-seq at early time points after naive CD8+ T cell activation, KDM6B inhibition (GSK-J4), in vivo viral challenge Cell Reports High 33730567
2021 The lncRNA DNM3OS physically interacts with KDM6B in the nucleus; this association induces TIAM1 expression through reduction of H3K27me3 at the TIAM1 promoter, promoting hepatocellular carcinoma proliferation, invasion, and metastasis driven by tumor-associated MSC-conditioned medium. Co-IP of DNM3OS-KDM6B, ChIP at TIAM1 promoter, KD/OE experiments, in vitro and in vivo HCC models Cancer Letters Medium 33472090
2018 KDM6B expression is upregulated by hypoxia (1% O2 or chemical mimics) in a HIF-2α-dependent manner (not HIF-1α); HIF-2α binds a hypoxia response element in the KDM6B promoter; KDM6B forms a complex with both HIF-2α and HIF-1α and acts as a potential co-activator of HIF-α target genes. RNAi for HIF-1α and HIF-2α, ChIP at KDM6B promoter (HRE), Co-IP of KDM6B-HIF-2α/HIF-1α, KDM6B KD effect on HIF-2α targets Acta Biochimica et Biophysica Sinica Medium 25520177
2021 KDM6B inhibition in myeloid cells (via genetic Kdm6b deletion or pharmacological GSK-J4 treatment) enhances antigen presentation, interferon response, and phagocytosis in myeloid cells by inhibiting mediators of immune suppression including Mafb, Socs3, and Sirpa; myeloid-specific Kdm6b deletion improves survival in glioblastoma mouse models and synergizes with anti-PD1 therapy. Single-cell and spatial transcriptomics, myeloid-specific Kdm6b KO mice (with GBM model), mechanistic studies of Mafb/Socs3/Sirpa, anti-PD1 combination experiments Nature Cancer High 37653141
2022 KDM6B cooperates with Tau protein in neurons; Tau interacts with and recruits KDM6B to the promoters of Slc17a7 (VGLUT1) and Slc17a6 (VGLUT2) genes, reducing H3K27me3 levels and inducing VGLUT1/2 expression; conditional KDM6B KO in excitatory neurons reduces spine density, synaptic vesicle number, and impairs learning and memory. KDM6B conditional KO in excitatory neurons, Co-IP of KDM6B-Tau, ChIP at VGLUT1/2 promoters, electrophysiology, behavioral tests Molecular Psychiatry High 36028572
2022 JMJD3 in wound macrophages directs early inflammation via JAK1,3/STAT3 signaling; in diabetic wounds, late IL-6-mediated JAK/STAT3 signaling sustains JMJD3 expression, which induces NF-κB-mediated inflammatory transcription via H3K27me3 removal; JMJD3-deficient myeloid cells show elevated STING (Tmem173) gene expression. scRNA-seq of human diabetic wounds, Jmjd3f/f Lyz2Cre+ mice, JAK/STAT pathway inhibitors, RNA-seq of wound macrophages, nanoparticle-based JMJD3 inhibition in vivo Cellular & Molecular Immunology High 36127466
2022 JMJD3 promotes cardiac fibrosis by demethylating H3K27me3 at the β-catenin promoter in activated cardiac fibroblasts, increasing β-catenin expression and downstream fibrogenic gene transcription (fibronectin, CTGF, collagen I/III); JMJD3 expression is induced by angiotensin II. ChIP at β-catenin promoter, JMJD3 inhibition (GSK-J4), β-catenin genetic KO, in vivo myocardial infarction model with JMJD3 inhibition Biochemical and Biophysical Research Communications Medium 32513540
2022 Kdm6b regulates motor neuron subtype diversification in the mouse spinal cord by acquiring cell fate specificity together with the transcription factor complex Isl1-Lhx3; Kdm6b promotes medial (MMC) and hypaxial (HMC) motor column fates while inhibiting lateral (LMC) and preganglionic (PGC) identities. Conditional Kdm6b KO in mouse motor neurons, single-cell RNA-seq, Isl1-Lhx3 transcription factor complex studies Nature Communications High 35177643
2021 KDM6B regulates HIF-1α-mediated transcriptional activation of Nox4 under intermittent hypoxia (IH) in an HIF-1-independent manner; pharmacological KDM6B blockade or shRNA silencing abolishes IH-induced HIF-1α binding to the Nox4 HRE promoter and prevents elevated catecholamines and hypertension in IH-exposed rats. ChIP (HIF-1α binding at Nox4 HRE), KDM6B shRNA and GSK-J4 inhibitor in PC12 cells, in vivo IH rat model with blood pressure monitoring Physiological Genomics Medium 34297635
2010 Jmjd3 is recruited to the proximal promoter of Mash1 via interaction with the transcription factor Hes1; Jmjd3 removes H3K27me3 at the Mash1 promoter to activate Mash1 expression during RA-induced neuronal differentiation of P19 cells; Co-IP confirms Jmjd3-Hes1 physical interaction. ChIP at Mash1 promoter, Co-IP of Jmjd3-Hes1, siRNA and dominant negative Jmjd3 mutant, overexpression in P19 cells, promoter-reporter assays Journal of Cellular Biochemistry High 20506217
2018 JMJD3 mediates doxorubicin-induced cardiomyopathy by reducing H3K27me3 at the SESN2 promoter, thereby suppressing SESN2 expression and leading to mitochondrial dysfunction and cardiomyocyte apoptosis; overexpression of SESN2 rescues JMJD3-induced cardiomyopathy. ChIP at SESN2 promoter, JMJD3 KD/OE, SESN2 rescue overexpression, mitochondrial function assays, human dilated cardiomyopathy tissue analysis Frontiers in Cell and Developmental Biology Medium 33117796
2018 Active KDM6B H3K27me3 demethylase activity is required for the global decrease in H3K27me3 between the 2-cell and 8-cell stages of bovine preimplantation development; KDM6B knockdown or catalytic inhibition prevents blastocyst formation, reduces ICM/TE cell numbers, and alters the embryonic transcriptome at the 8-cell stage. Maternal KDM6B mRNA knockdown in bovine embryos, catalytic inhibitor (KDM6B-specific), global H3K27me3 immunostaining, transcriptome analysis at 8-cell stage Epigenetics High 29160132
2019 KDM6B epigenetically activates neuronal differentiation genes in neuroblastoma by removing H3K27me3; KDM6B functions downstream of the retinoic acid-HOXC9 axis; KDM6B is induced by retinoic acid via HOXC9, and KDM6B physically interacts with HOXC9 to target neuronal gene loci for epigenetic activation. ChIP at neuronal gene loci, KDM6B KD and OE, retinoic acid treatment, Co-IP of KDM6B-HOXC9, neuroblastoma cell differentiation assays Oncogenesis High 30631055
2021 JMJD3 promotes TGF-β-induced EMT in Ras-activated lung cancer cells by epigenetically inducing syntenin expression through removal of H3K27me3 at the syntenin promoter; syntenin then regulates TGF-β receptor activation; JMJD3 expression is regulated by Ras activity. ChIP at syntenin promoter, Co-IP of JMJD3-syntenin, JMJD3 KD/OE, TGF-β-Smad activation assays, tissue array analysis Oncogenesis Medium 33637682
2015 KDM6B directly interacts with FOXO1 in NSCLC cells; KDM6B overexpression promotes nuclear translocation/accumulation of FOXO1, initiating mitochondria-dependent apoptosis; KDM6B-induced apoptosis and anti-metastatic effects are abrogated by FOXO1 knockdown. Co-IP of KDM6B-FOXO1, nuclear fractionation, FOXO1 KD epistasis, apoptosis and invasion assays in NSCLC cells Cellular Physiology and Biochemistry Medium 26303949
2021 The Notch-effector CSL directly represses KDM6B transcription in keratinocytes and SCC cells; increased CSL levels suppress KDM6B, enhancing proliferative potential; CSL silencing induces KDM6B, promoting growth arrest, apoptosis, and differentiation in SCC. Global transcriptomics of CSL-silenced HKCs and SCC cells, ChIP for CSL at KDM6B promoter (implied by direct target designation), in vivo SCC tumor models Journal of Clinical Investigation Medium 29757189
2022 ERα is recruited to the KDM6B promoter upon estrogen stimulation, directly enhancing KDM6B expression; KDM6B is then recruited to BMP2 and HOXC6 promoters, removing H3K27me3 and activating osteogenic transcription; KDM6B depletion abolishes estrogen's pro-osteogenic effects in vivo. ChIP of ERα at KDM6B promoter and KDM6B at BMP2/HOXC6 promoters, KDM6B shRNA in DMSCs, in vivo calvarial bone regeneration model Bone Research High 34992221
2017 Jmjd3, but not Utx, is required for axial skeletal patterning in mice; Jmjd3 mutant embryos display anterior homeotic transformation associated with reduced Hox gene expression; ChIP in embryonic tailbuds shows elevated H3K27me3 at Hox loci in Jmjd3 mutants; demethylase-inactive Jmjd3 mutants phenocopy the Jmjd3 knockout. Jmjd3 knockout and demethylase-inactive mutant mice, ChIP at Hox loci in tailbuds, microarray gene expression analysis FASEB Journal High 28188179

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2012 Histone demethylases KDM4B and KDM6B promotes osteogenic differentiation of human MSCs. Cell stem cell 285 22770241
2012 Histone demethylase KDM6B promotes epithelial-mesenchymal transition. The Journal of biological chemistry 142 23152497
2011 KDM6B/JMJD3 histone demethylase is induced by vitamin D and modulates its effects in colon cancer cells. Human molecular genetics 137 21890490
2021 Cancer-derived exosomal miR-138-5p modulates polarization of tumor-associated macrophages through inhibition of KDM6B. Theranostics 136 34093857
2013 Jmjd3 inhibits reprogramming by upregulating expression of INK4a/Arf and targeting PHF20 for ubiquitination. Cell 128 23452852
2015 JMJD3 as an epigenetic regulator in development and disease. The international journal of biochemistry & cell biology 121 26193001
2021 Inhibition of macrophage histone demethylase JMJD3 protects against abdominal aortic aneurysms. The Journal of experimental medicine 119 33779682
2014 Histone demethylase Jumonji D3 (JMJD3/KDM6B) at the nexus of epigenetic regulation of inflammation and the aging process. Journal of molecular medicine (Berlin, Germany) 117 24925089
2011 The H3K27me3 demethylase, KDM6B, is induced by Epstein-Barr virus and over-expressed in Hodgkin's Lymphoma. Oncogene 114 21242977
2020 Temperature-dependent sex determination is mediated by pSTAT3 repression of Kdm6b. Science (New York, N.Y.) 112 32299951
2022 Macrophage-specific inhibition of the histone demethylase JMJD3 decreases STING and pathologic inflammation in diabetic wound repair. Cellular & molecular immunology 110 36127466
2021 Histone H3K27 methyltransferase EZH2 and demethylase JMJD3 regulate hepatic stellate cells activation and liver fibrosis. Theranostics 96 33391480
2015 Histone H3 Lysine 27 demethylases Jmjd3 and Utx are required for T-cell differentiation. Nature communications 95 26328764
2021 Exosomal microRNA-22-3p alleviates cerebral ischemic injury by modulating KDM6B/BMP2/BMF axis. Stem cell research & therapy 86 33546766
2017 DHEA inhibits acute microglia-mediated inflammation through activation of the TrkA-Akt1/2-CREB-Jmjd3 pathway. Molecular psychiatry 86 28894299
2016 Neuronal activity controls Bdnf expression via Polycomb de-repression and CREB/CBP/JMJD3 activation in mature neurons. Nature communications 86 27010597
2018 Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia. Journal of cancer research and clinical oncology 80 29594337
2016 Histone H3K27 Demethylase JMJD3 in Cooperation with NF-κB Regulates Keratinocyte Wound Healing. The Journal of investigative dermatology 80 26802933
2016 Histone demethylases in physiology and cancer: a tale of two enzymes, JMJD3 and UTX. Current opinion in genetics & development 78 27151432
2015 Jmjd3-Mediated H3K27me3 Dynamics Orchestrate Brown Fat Development and Regulate White Fat Plasticity. Developmental cell 78 26625958
2014 The histone lysine demethylase JMJD3/KDM6B is recruited to p53 bound promoters and enhancer elements in a p53 dependent manner. PloS one 74 24797517
2018 Fasting-induced JMJD3 histone demethylase epigenetically activates mitochondrial fatty acid β-oxidation. The Journal of clinical investigation 73 29911994
2021 KDM6B-mediated histone demethylation of LDHA promotes lung metastasis of osteosarcoma. Theranostics 72 33664867
2013 Jmjd3 controls mesodermal and cardiovascular differentiation of embryonic stem cells. Circulation research 66 23856522
2022 JMJD3 activated hyaluronan synthesis drives muscle regeneration in an inflammatory environment. Science (New York, N.Y.) 65 35926054
2020 JMJD3 and UTX determine fidelity and lineage specification of human neural progenitor cells. Nature communications 60 31959746
2017 Kdm6b regulates cartilage development and homeostasis through anabolic metabolism. Annals of the rheumatic diseases 60 28314754
2016 Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs. Haematologica 58 27742770
2018 Cystathionine-γ-lyase ameliorates the histone demethylase JMJD3-mediated autoimmune response in rheumatoid arthritis. Cellular & molecular immunology 56 29844591
2017 Regulation of the JMJD3 (KDM6B) histone demethylase in glioblastoma stem cells by STAT3. PloS one 53 28384648
2019 Kdm6b regulates context-dependent hematopoietic stem cell self-renewal and leukemogenesis. Leukemia 52 30936419
2017 JMJD3 and NF-κB-dependent activation of Notch1 gene is required for keratinocyte migration during skin wound healing. Scientific reports 51 28747631
2019 The role and prospect of JMJD3 in stem cells and cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 50 31545292
2022 Type I interferon antagonism of the JMJD3-IRF4 pathway modulates macrophage activation and polarization. Cell reports 48 35443173
2023 Jumonji domain-containing protein-3 (JMJD3) promotes myeloid fibroblast activation and macrophage polarization in kidney fibrosis. British journal of pharmacology 47 37076137
2012 RNA polymerase II progression through H3K27me3-enriched gene bodies requires JMJD3 histone demethylase. Molecular biology of the cell 47 23243002
2021 SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade. Nature communications 46 34262032
2020 Jmjd3 regulates inflammasome activation and aggravates DSS-induced colitis in mice. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 46 31971317
2014 Histone demethylase Jmjd3 is required for the development of subsets of retinal bipolar cells. Proceedings of the National Academy of Sciences of the United States of America 46 24572572
2013 EED and KDM6B coordinate the first mammalian cell lineage commitment to ensure embryo implantation. Molecular and cellular biology 46 23671187
2021 Activation of GPR40 attenuates neuroinflammation and improves neurological function via PAK4/CREB/KDM6B pathway in an experimental GMH rat model. Journal of neuroinflammation 45 34275493
2020 Palmitate-TLR4 signaling regulates the histone demethylase, JMJD3, in macrophages and impairs diabetic wound healing. European journal of immunology 45 32662520
2021 KDM6B is an androgen regulated gene and plays oncogenic roles by demethylating H3K27me3 at cyclin D1 promoter in prostate cancer. Cell death & disease 43 33414463
2021 The miRNA-15b/USP7/KDM6B axis engages in the initiation of osteoporosis by modulating osteoblast differentiation and autophagy. Journal of cellular and molecular medicine 43 33434305
2020 JmjC-KDMs KDM3A and KDM6B modulate radioresistance under hypoxic conditions in esophageal squamous cell carcinoma. Cell death & disease 42 33318475
2022 The ERα/KDM6B regulatory axis modulates osteogenic differentiation in human mesenchymal stem cells. Bone research 39 34992221
2021 KDM6B promotes activation of the oncogenic CDK4/6-pRB-E2F pathway by maintaining enhancer activity in MYCN-amplified neuroblastoma. Nature communications 39 34893606
2014 MIR146A inhibits JMJD3 expression and osteogenic differentiation in human mesenchymal stem cells. FEBS letters 39 24726732
2016 ISL1 and JMJD3 synergistically control cardiac differentiation of embryonic stem cells. Nucleic acids research 38 27105846
2021 KDM6B (JMJD3) and its dual role in cancer. Biochimie 36 33581195
2019 Genetic variants in the KDM6B gene are associated with neurodevelopmental delays and dysmorphic features. American journal of medical genetics. Part A 36 31124279
2023 Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockade. Nature cancer 35 37653141
2021 Epigenetic regulation of TGF-β-induced EMT by JMJD3/KDM6B histone H3K27 demethylase. Oncogenesis 35 33637682
2021 JMJD3: a critical epigenetic regulator in stem cell fate. Cell communication and signaling : CCS 35 34217316
2016 Alcohol-induced suppression of KDM6B dysregulates the mineralization potential in dental pulp stem cells. Stem cell research 35 27286573
2018 KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice. Blood advances 34 30275007
2018 JMJD3 inhibition protects against isoproterenol-induced cardiac hypertrophy by suppressing β-MHC expression. Molecular and cellular endocrinology 33 29753027
2022 Histone demethylase JMJD3 downregulation protects against aberrant force-induced osteoarthritis through epigenetic control of NR4A1. International journal of oral science 32 35831280
2018 Active H3K27me3 demethylation by KDM6B is required for normal development of bovine preimplantation embryos. Epigenetics 32 29160132
2017 Regulation of Epigenetic Modifiers, Including KDM6B, by Interferon-γ and Interleukin-4 in Human Macrophages. Frontiers in immunology 32 28228757
2019 Histone demethylase KDM6B has an anti-tumorigenic function in neuroblastoma by promoting differentiation. Oncogenesis 29 30631055
2019 Enhancer-mediated enrichment of interacting JMJD3-DDX21 to ENPP2 locus prevents R-loop formation and promotes transcription. Nucleic acids research 29 31251802
2017 Histone demethylases UTX and JMJD3 are required for NKT cell development in mice. Cell & bioscience 29 28529687
2016 Histone demethylase JMJD3 at the intersection of cellular senescence and cancer. Biochimica et biophysica acta 29 26957416
2018 A new metabolic gene signature in prostate cancer regulated by JMJD3 and EZH2. Oncotarget 28 29805743
2018 Inhibiting Jumoji domain containing protein 3 (JMJD3) prevent neuronal apoptosis from stroke. Experimental neurology 28 30028997
2014 The histone lysine demethylase Kdm6b is required for activity-dependent preconditioning of hippocampal neuronal survival. Molecular and cellular neurosciences 28 24983519
2020 Histone Demethylase JMJD3 Mediated Doxorubicin-Induced Cardiomyopathy by Suppressing SESN2 Expression. Frontiers in cell and developmental biology 27 33117796
2019 Comprehensive profiling of JMJD3 in gastric cancer and its influence on patient survival. Scientific reports 27 30696880
2010 Jmjd3 activates Mash1 gene in RA-induced neuronal differentiation of P19 cells. Journal of cellular biochemistry 27 20506217
2021 Tumor-associated mesenchymal stem cells promote hepatocellular carcinoma metastasis via a DNM3OS/KDM6B/TIAM1 axis. Cancer letters 26 33472090
2021 Polycomb represses a gene network controlling puberty via modulation of histone demethylase Kdm6b expression. Scientific reports 26 33479437
2019 EZH2, JMJD3, and UTX epigenetically regulate hepatic plasticity inducing retro-differentiation and proliferation of liver cells. Cell death & disease 26 31285428
2018 Dynamics of chromatin marks and the role of JMJD3 during pancreatic endocrine cell fate commitment. Development (Cambridge, England) 26 29559448
2018 Notch-effector CSL promotes squamous cell carcinoma by repressing histone demethylase KDM6B. The Journal of clinical investigation 26 29757189
2018 Virtual Fragment Screening Identification of a Quinoline-5,8-dicarboxylic Acid Derivative as a Selective JMJD3 Inhibitor. ChemMedChem 25 29633584
2015 KDM6B Elicits Cell Apoptosis by Promoting Nuclear Translocation of FOXO1 in Non-Small Cell Lung Cancer. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 25 26303949
2022 Jmjd3/IRF4 axis aggravates myeloid fibroblast activation and m2 macrophage to myofibroblast transition in renal fibrosis. Frontiers in immunology 24 36159833
2021 KDM6B-dependent chromatin remodeling underpins effective virus-specific CD8+ T cell differentiation. Cell reports 23 33730567
2021 microRNA-106b derived from endothelial cell-secreted extracellular vesicles prevents skin wound healing by inhibiting JMJD3 and RIPK3. Journal of cellular and molecular medicine 23 33734576
2020 Targeting JMJD3 histone demethylase mediates cardiac fibrosis and cardiac function following myocardial infarction. Biochemical and biophysical research communications 23 32513540
2023 The clinical and molecular spectrum of the KDM6B-related neurodevelopmental disorder. American journal of human genetics 22 37196654
2017 New insights into the role of Jmjd3 and Utx in axial skeletal formation in mice. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 22 28188179
2022 KDM6B cooperates with Tau and regulates synaptic plasticity and cognition via inducing VGLUT1/2. Molecular psychiatry 21 36028572
2021 The Functions of the Demethylase JMJD3 in Cancer. International journal of molecular sciences 21 33478063
2021 KDM6B promotes ESCC cell proliferation and metastasis by facilitating C/EBPβ transcription. BMC cancer 21 34001062
2015 Kdm6b and Pmepa1 as Targets of Bioelectrically and Behaviorally Induced Activin A Signaling. Molecular neurobiology 20 26215835
2014 Regulation of histone demethylase KDM6B by hypoxia-inducible factor-2α. Acta biochimica et biophysica Sinica 20 25520177
2022 The histone demethylase Kdm6b regulates subtype diversification of mouse spinal motor neurons during development. Nature communications 19 35177643
2022 KDM6B promotes gastric carcinogenesis and metastasis via upregulation of CXCR4 expression. Cell death & disease 18 36564369
2021 Allyl sulfide promotes osteoblast differentiation and bone density via reducing mitochondrial DNA release mediated Kdm6b/H3K27me3 epigenetic mechanism. Biochemical and biophysical research communications 18 33556823
2021 Histone demethylase KDM6B inhibits breast cancer metastasis by regulating Wnt/β-catenin signaling. FEBS open bio 17 34165914
2019 JMJD3 regulates CD4 T cell trafficking by targeting actin cytoskeleton regulatory gene Pdlim4. The Journal of clinical investigation 17 31393857
2024 Curcumenol regulates Histone H3K27me3 demethylases KDM6B affecting Succinic acid metabolism to alleviate cartilage degeneration in knee osteoarthritis. Phytomedicine : international journal of phytotherapy and phytopharmacology 16 39126921
2022 JMJD3/H3K27me3 epigenetic modification regulates Th17/Treg cell differentiation in ulcerative colitis. International immunopharmacology 16 35777266
2021 Lysine demethylase KDM6B regulates HIF-1α-mediated systemic and cellular responses to intermittent hypoxia. Physiological genomics 16 34297635
2020 Sodium lactate promotes stemness of human mesenchymal stem cells through KDM6B mediated glycolytic metabolism. Biochemical and biophysical research communications 16 32891432
2018 Epigenetic Regulation of EMT (Epithelial to Mesenchymal Transition) and Tumor Aggressiveness: A View on Paradoxical Roles of KDM6B and EZH2. Epigenomes 16 34991274
2017 The Roles of Histone Demethylase Jmjd3 in Osteoblast Differentiation and Apoptosis. Journal of clinical medicine 16 28241471
2016 The Roles of Histone Demethylase UTX and JMJD3 (KDM6B) in Cancers: Current Progress and Future Perspectives. Current medicinal chemistry 16 27458035